首页|姜黄素脂质包裹纳米粒的制备及药动学研究

姜黄素脂质包裹纳米粒的制备及药动学研究

扫码查看
制备了基于脂质包裹中空介孔二氧化硅纳米粒的姜黄素递药系统(CUR-HMSN@lip),对其处方工艺参数进行优化,并考察了在大鼠体内的药动学行为.采用TEM、PXRD、ζ电位和热重分析法对CUR-HMSN@lip进行表征,结果说明负载姜黄素的中空介孔二氧化硅纳米粒(CUR-HMSN)成功被磷脂包裹.口服给予大鼠CUR-HMSN@lip后,tmax为(1.83±0.41)h,AUClast 为(570.82±48.07)h·ng·mL-1,MRTlast 为(5.68±1.21)h;与 CUR-HMSN 处理组相比,CUR-HMSN@lip 处理组的药-时曲线未出现双峰现象;CUR-HMSN@lip的相对生物利用度为203.8%.该研究表明,CUR-HMSN@lip递药系统能提高姜黄素的生物利用度,改善CUR-HMSN的突释现象.
Preparation and Pharmacokinetic Study of the Lipid-coated Curcumin Nanoparticles
A drug delivery system of lipid-coated hollow mesoporous silica nanoparticles for curcumin(CUR-HMSN@lip)was constructed.Its formulation and process parameters were optimized,and its pharmacokinetic behavior in rats was investigated.The obtained CUR-HMSN@lip was characterized by TEM,PXRD,ζ potential,and thermogravimetric analyses,and the results indicated that the curcumin-loaded hollow mesoporous silica nanoparticles(CUR-HMSN)were successfully encapsulated by phospholipids.After orally administered of CUR-HMSN@lip to rats,the pharmacokinetic parameters of curcumin were determined and calculated.The results were as follows:tmax was(1.83±0.41)h,AUClast was(570.82±48.07)h·ng·mL-1,and MRTlast was(5.68±1.21)h.Compared with the CUR-HMSN treatment group,the plasma concentration-time curve of the CUR-HMSN@lip treatment group did not show a double peak phenomenon.The relative bioavailability of CUR-HMSN@lip was 203.8%.It was concluded that the CUR-HMSN@lip delivery system increased the bioavailability of curcumin and improved the burst release of CUR-HMSN.

phospholipidhollow mesoporous silica nanoparticlecurcumindrug delivery systemburst releasebioavailability

程子明、薛雪

展开 >

同方药业集团有限公司,北京 102100

悦康药业集团股份有限公司,北京 100176

磷脂 中空介孔二氧化硅纳米粒 姜黄素 递药系统 突释 生物利用度

2024

中国医药工业杂志
上海医药工业研究院,中国化学制药工业协会

中国医药工业杂志

CSTPCD
影响因子:0.487
ISSN:1001-8255
年,卷(期):2024.55(6)